SCHEMBL2655753

SCHEMBL2655753

COc1ccccc1-c1cccc2c(N)c3c(nc12)CN(C1=CC=C1)C3=O

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ UGCG Q16739 5/20 0.39
▸ ADORA2A P29274 2/20 0.36
▸ ADORA1 P30542 1/20 0.36
▸ ACHE P22303 1/20 0.35
▸ GABRG2 P18507 3/20 0.35
▸ GABRB3 P28472 3/20 0.35
▸ GABRA2 P47869 3/20 0.35
▸ MEN1 O00255 2/20 0.34
▸ ALDH1A1 P00352 2/20 0.34
▸ MAPT P10636 2/20 0.34
▸ RAB9A P51151 2/20 0.34
▸ KMT2A Q03164 2/20 0.34
▸ SMN1; SMN2 Q16637 2/20 0.34
▸ MAPK3 P27361 2/20 0.33
▸ MAPK1 P28482 2/20 0.33
▸ MAP2K1 Q02750 2/20 0.33
▸ C1R P00736 1/20 0.33
▸ JAK2 O60674 1/20 0.33
▸ DPP4 P27487 1/20 0.33
▸ NPC1 O15118 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2658032 0.92 UGCG (0.33) UGCGADORA2AADORA1ACHEGABRG2
SCHEMBL2657086 0.91 UGCG (0.36) UGCGADORA2AGABRG2GABRB3GABRA2
SCHEMBL2658318 0.91 GABRG2 (0.37) UGCGGABRG2GABRB3GABRA2RAB9A
SCHEMBL2657791 0.91 GABRG2 (0.43) UGCGADORA2AGABRG2GABRB3GABRA2
SCHEMBL2655844 0.90 GABRG2 (0.37) UGCGADORA2AGABRG2GABRB3GABRA2
SCHEMBL4919724 0.90 CRHR1 (0.41) GABRG2GABRB3GABRA2MEN1ALDH1A1
SCHEMBL2660785 0.90 GABRG2 (0.43) UGCGGABRG2GABRB3GABRA2RAB9A
SCHEMBL4912616 0.90 GABRG2 (0.48) GABRG2GABRB3GABRA2MEN1ALDH1A1
SCHEMBL2660107 0.89 ALDH1A1 (0.36) UGCGADORA2AADORA1ACHEGABRG2
SCHEMBL2655981 0.89 CRHR1 (0.38) GABRG2GABRB3GABRA2MEN1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2176263-A2 FUSED QUINOLINE DERIVATIVES USEFUL AS GABA MODULATORS AstraZeneca AB (SE) 2010-04-21 — — EP claimed
US-20080318943-A1 Compounds and Uses Thereof - 848 ASTRAZENECA AB (SE) 2008-12-25 — — US claimed
WO-2008155572-A2 FUSED QUINOLINE DERIVATIVES USEFUL AS GABA MODULATORS ASTRAZENECA AB (SE) 2008-12-24 — — WO claimed
EP-2176263-A2 FUSED QUINOLINE DERIVATIVES USEFUL AS GABA MODULATORS AstraZeneca AB (SE) 2010-04-21 — — EP disclosed
US-20080318943-A1 Compounds and Uses Thereof - 848 ASTRAZENECA AB (SE) 2008-12-25 — — US disclosed
WO-2008155572-A2 FUSED QUINOLINE DERIVATIVES USEFUL AS GABA MODULATORS ASTRAZENECA AB (SE) 2008-12-24 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080318943-A1 Compounds and Uses Thereof - 848 COMT, BACE1, BDNF UGCG 2572/4885ADORA2A 440/4885ADORA1 694/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback